IGF1 and cancer: Within the HNSCC dataset, ~ 50% of PI16 labelled fibroblasts from tumour samples were labelled as IGF1 + CAF in the pan-cancer analysis, suggesting that this phenotype is an early/low activation phenotype consistent with previous studies [1, 47].